A prospective randomized study comparing poly-ATG to mono-OKT3 clonal antibodies for the first rejection therapy after kidney transplantation: long-term results.
Baldi
A
A
Department of Renal Transplantation, Catholic University of Louvain Medical School, Brussels, Belgium.
Malaise
J
J
Mourad
M
M
Squifflet
J P
JP
D000206:Actuarial Analysis; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology / Q000401:mortality / Q000502:physiology*; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D015996:Survival Rate; D013997:Time Factors
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3